Anzeige
Meldung des Tages: USA erklären Kupfer zur Chefsache – dieser Nevada-Explorer bohrt bereits

Carlisle News

Aktie
WKN:  871884 ISIN:  US1423391002 US-Symbol:  CSL Branche:  Baumaterialien Land:  USA
354,56 $
-20,22 $
-5,40%
305,21 € 06.03.26
Depot/Watchlist
Marktkapitalisierung *
11,73 Mrd. €
Streubesitz
-
KGV
17,11
Dividende
3,74 EUR
Dividendenrendite
1,37%
Nachhaltigkeits-Score
15 %
Index-Zuordnung
-

Carlisle News

06.03.26 - BNP Paribas
Carlisle Companies – Bei der Profitabilität die Branche klar anführen
Der US-​Bauzulieferer hat mit einem schwierigen Umfeld zu kämpfen. Dennoch sieht sich das Management gut unterwegs in Richtung der Langfristziele.
07.12.25 - PR Newswire
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-​drlb) Over Five Years PR Newswire
28.10.25 - PR Newswire
CSL wurde von der International Society for Pharmaceutical Engineering (ISPE) als Gesamtsieger der „2025 Facility of the Year Awards" ausgezeichnet
CSL wurde von der International Society for Pharmaceutical Engineering (ISPE) als Gesamtsieger der „2025 Facility of the Year Awards" ausgezeichnet PR Newswire
26.10.25 - PR Newswire
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE) PR Newswire
26.10.25 - PR Newswire
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE) PR Newswire
21.10.25 - PR Newswire
Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
Recent RWE Data Show Cell-​Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-​Confirmed Influenza in Pediatric and Adult Populations Relative to ...
26.09.25 - PR Newswire
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy PR Newswire
04.07.25 - wallstreetONLINE Redaktion
Aktien mit Potenzial: JPMorgan’s "Analyst Focus List" für Juli
JPMorgan hat für Juli seine "Analyst Focus List" aktualisiert: Darunter spannende Aktien wie Scholar Rock, Carlisle und Boeing mit viel Potenzial. Das sind die Top-​Empfehlungen ...
16.06.25 - PR Newswire
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-​gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-...
23.05.25 - PR Newswire
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy PR Newswire
23.05.25 - PR Newswire
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy PR Newswire
29.04.25 - PR Newswire
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy PR Newswire
29.04.25 - PR Newswire
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy PR Newswire

Newssuche

Videos

newspaper
04.03.26 +13,80%
ROHÖL mit Ziel MINUS 40$?!?
Fundierte Strategien für den Handel der wichtigen News in einem Seminarpaket, plus transparenter ... Mehr »